Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Strata Critical Medical (SRTA) Operating Leases (2020 - 2025)

Historic Operating Leases for Strata Critical Medical (SRTA) over the last 6 years, with Q3 2025 value amounting to $2.8 million.

  • Strata Critical Medical's Operating Leases fell 8813.55% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year decrease of 8813.55%. This contributed to the annual value of $2.3 million for FY2024, which is 8816.5% down from last year.
  • As of Q3 2025, Strata Critical Medical's Operating Leases stood at $2.8 million, which was down 8813.55% from $5.3 million recorded in Q2 2025.
  • Strata Critical Medical's Operating Leases' 5-year high stood at $25.5 million during Q1 2024, with a 5-year trough of $278000.0 in Q4 2021.
  • Its 5-year average for Operating Leases is $12.3 million, with a median of $10.5 million in 2022.
  • In the last 5 years, Strata Critical Medical's Operating Leases skyrocketed by 528489.21% in 2022 and then tumbled by 8816.5% in 2024.
  • Quarter analysis of 5 years shows Strata Critical Medical's Operating Leases stood at $278000.0 in 2021, then skyrocketed by 5284.89% to $15.0 million in 2022, then skyrocketed by 31.85% to $19.7 million in 2023, then plummeted by 88.16% to $2.3 million in 2024, then increased by 20.59% to $2.8 million in 2025.
  • Its last three reported values are $2.8 million in Q3 2025, $5.3 million for Q2 2025, and $5.7 million during Q1 2025.